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The alkylphospholipid hexadecylphosphocholine (HePC), 
member of a new class of antineoplastic drugs, has been pre-
viously shown to exert cytotoxic effects on neoplastic cell 
lines in vitro, and a selective antineoplastic activity has been 
reported after topical apflication of He PC in I/ivo, in particu-
lar on skin metastases 0 human mammary carcinomas. Pre-
liminary observations suggest that HePC might also be bene-
ficial in the treatment of non-neoplastic skin diseases 
characterized by epidermal hyperplasia such as psoriasis. 
Therefore, we investigated whether HePC might inhibit the 
proliferation of normal human keratinocytes, and whether its 
effects might be dependent upon the proliferative status of 
the treated cells. Moreover, its effects on phosphatidylcho-
line biosynthesis were studied in keratinocytes. HePC dose-
dependently decreased cell numbers, thymidine incorpora-
tion, and protein synthesis when applied during the growth 
phase of keratinocytes grown in serum-free medium, with a 
For more than 30 years, lysophosphatidylcholines and ether-linked lysophosphatidylcholines (etherlipids) have been known to exert antineoplastic effects [1]. Inves-tigations on the minimal structural requirements for lysophosphatidylcholines and related compounds to 
exert an antitumoral action revealed alkylphosphocholines as a new 
class of antineoplastic drugs [1,2] that show antitumoral properties 
as potent as those of the well known lysophosphatidylcholines 
1-0-octadecy l-2-0-methyl-rac-glycero-3-phosphocholine (Et-18-
OCH3) and BM41.440 (21. 
The most prominent representative of this group of compounds, 
hexadecylphosphocholine (HePC; Fig 1), exerts a pronounced cy-
totoxic action on different neoplastic cell lines in vitro [3,4] and a 
selective antineoplastic activity in vivo (5 -7]. In particular, topical 
application of HePC has been shown to be successful in the treat-
ment of skin metastases of human mammary carcinomas [8], and its 
activity against mammary tumors was superior to that of cyclophos-
phamide in animal experiments [5] . Compared with other alkyl-
phosphatidylcholines, HePC has the advantage that it is only slowly 
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minimal inhibitory dose of 10-7 molll for thymidine incor-
poration, 3 X 10-7 molll for cell numbers, and 10-6 molll 
for 35S-methionine incorporation. No major differences were 
observed when keratinocytes were grown under high-Ca++ 
conditions. In contrast, slowly proliferating confluent kerat-
inocyte cultures showed growth inhibition only after 10-4 
molll HePe. Phosphatidylcholine biosynthesis was dose-
dependently inhibited by HePC with a half inhibitory con-
centration of 3 X 10-6 mol/I, and with translocation of the 
rate-limiting enzyme, CTP:phosphocholine cytidylyltrans-
ferase, to the cytosol, where the enzyme is inactive. These 
data show a pronounced antiproliferative effect of He PC also 
on proliferating non-malignant keratinocytes, and are com-
patible with its possible action on hyperproliferative skin 
disorders. Key words: hexadecylphosphocholinelphosphatidylcho-
Ii nel antiluoplastic activity Ipsoriasis. ] Invest Dermatol1 02:490-
494, 1994 
and poorly metabolized, mainly by cleavage of the choline head 
group [9]. Moreover, blood samples of patients treated with HePC 
were free of this compound, demonstrating lack of absorption even 
after extensive topical treatment [10] . 
These data suggest that HePC might be a useful agent in the 
adjuvant therapy of skin metastases of mammary carcinomas, but 
possibly also of cutaneous malignancies such as cutaneous T-cell 
lymphomas and others [10]. Moreover, as it had been claimed that 
HePC exerts a selective anti proliferative effect on proliferating 
neoplastic cells ill vivo [5 - 71 and as we and others had previously 
shown that HePC inhibits protein kinase C ill vitro [11-13] that is 
involved in the regulation of keratinocyte proliferation, it was 
tempting to speculate whether HePC might also be effective in 
non-neoplastic skin diseases characterized by epidermal hyperplasia 
such as psoriasis . As preliminary clinical observations were compati-
ble with this hypothesis (WR, personal observation), we aimed to 
investigate whether HePC might also inhibit the growth of non-
transformed, normal human keratinocytes, and whether a potential 
antiproliferative effect of HePC might be dependent upon the hy-
perproliferative status of the treated cells. As alkylphospholipids are 
readily bound to serum proteins such as serum albumin or lipopro-
teins, lowering their uptake rate into the cells and decreasing their 
biologic activity [1,14,15], all experiments were carried out on kerat-
inocytes grown in serum-free medium. To exclude a dependency of 
HePC effects upon the Ca++ concentration, comparative experi-
ments were performed in low-Ca++ and in high-Ca++ medium. 
Moreover, we were interested in whether HePC might exert its 
antiproliferative effects by interference with the biosynthesis of 
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Figure 1. Chemical structure of hexadecylphosphocholine. 
phosphatidy lcholine in keratinocytes, as w e had recently demon-
strated in M adin-Darby canine kidney cells [1 6]. There fore, choline 
incorporation into phosphatidylcholine and the intracellular loca li-
zation of th e rate-limiting enzyme, CTP:phosphocholine cytidyly l-
transferase, were studied under th e influe nce of HePe. 
MATERIALS AND METHODS 
Reagents (Methy!-3H]choline chloride (2.8 -3.1 TBqjmmol) , ' H-thy-
midine (50 - 70 Cijmmol) , '5S-methionine (37 TBqjmmol) , and [Methyl-
14C]-phosphocholine (20 Bq/ nmol) were purchased from Amersham 
(Braunschwei g, Germany). Hexadecylphosphocholine (HePC) was synthe-
sized in twO steps from the tetra-n-butyl-ammonium salt of phosphocholine 
and I-bromohexadecane, and purified by column chromatography on silica 
gel as described (17] . Dith iothreitol, digitonin, and lipid standards were 
from Sigma. 
Cell Culture Six-millimeter punch biopsies were obtained from the 
lower back of healthy volunteers, and normal human epidermal keratino-
cyees were isolated as described [18] . Keratinocytes were then suspended in 
serum-free keratinocyte basa l medium (Clonetics, San Diego, CA), supple-
mented with 10 ng/ml epidermal growth factor,S J.Lg/ml insulin, 0.5 J.LM 
hydrocortisone, 50 J.Lg/ml bovine pituitary extract, 100 J.Lg/ml penicillin/ 
streptomycin, and 2.5 J.Lg/ml fungizone (all purchased from C lonetics), and 
were plated in 80-mm plastic Petri dishes (Costar, Cambridge, MA) with a 
seeding density of 1 X 104 viable cells/cm2. The cells were incubated at 
37° C in 100% humidity in an atmosphere of 95% air, 5% CO2, The me-
dium was replaced every 2 d, and the cells were passaged before confluency. 
For all experiments, kerati nocytes were used at second passage. 
Proliferation Assays All proliferation assays were performed on kerati-
nocytes grown in low-Ca-H- medium (0.15 mM) and on keratinocytes grown 
in high-Ca-H-medium (1.1 mM). For determination oPH-thymidine incor-
poration into DNA, second-passage kcratinocytes were seeded in 24-wcll 
tissue culture clusters (Costar) with a seeding density of 1 X 10' cells/cm2. 
The following day, triplica te cultures were incubated either with medium 
alone or with medium containing 10- 4 _10-8 Moljl HePC. Fresh medium 
containing HePC was added after 2 d. After 4 d, keratinocyte cultures were 
incubated for 6 h at 37"C with 1 J.lCijml ' H-thymidine (50-70 CijmM). 
The incorporation oPH-thymidine was stopped by medium aspiration fol-
lowed by two washes wi th cold phosphate-buffered saline (PBS) and the 
addition of cold 6% trichl oroacetic acid. The incorporated radioactivity was 
determined by liquid scintillation counting as described elsewhere [1 9]. and 
the results shown represent mean values ± SO of three separate experiments 
conducted in duplica te. 
In addition, cell prolifera tion was assessed by the MUH fluorescence assay 
[20]. Keratinocytes were seeded in 96-multiwell plastic tissue culture plates 
(Falcon) with a density of 5 X 10' cells/cm2 and treated with HePC as 
described above. Five wells for each concentration were treated identically. 
After 4 d, the cells were washed twice with PBS and were incubated with 
100 J.l1 4-methylumbelli fery l heptanoate (MUH; Serva, Heidelberg, Ger-
many; 100 J.lg/ml in PBS) at 37"C for 1 h. The resulting fluorescence was 
measured using a Fluoroscan II devicc (Flow Laboratory, Meckenheim, 
Germany) as previously described [20,21] . MUH is hydrolyzed by ce ll ester-
ases, and the amount of measurcd fluorescence is proportional to the nlllnbcr 
of viable cc lls (20]. The resu lts are given as absolute fluorescence units (AFU) 
and were calculated as means ± SO from five different wells. The experi-
ments were repeated with identical results. 
In furth cr experiments, the time dependcncy of HePC cffects on kerati-
nocyte proliferation was examined by adding 10- 5 _ 10- 7 M HePC for 2, 4, 
6, 8,24,48,72, or 96 h. Thercafter, 'H-thymidine incorporation and MUH 
fluoresce nce were detcrmined as described above. In addition, confluent 
cultures were trea ted with HePC (10- 4- 10- 8 M) for 4 d, to test whether 
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HePC effects o n keratinocyte proliferation were dependent upon the prolif-
erative status of the treated ceLls. 
Determination of Protein Synthesis Keratinocytes were treated with 
HePC in various concentrations for 4 d as described above. During the last 
12 h of culture, '5S-methionine (10 J.LCijml) was added to the cultures. 
Thereafter, protcin-bound radioactivity was measured by acid precipitation 
using a modification of the method of Mans and Novelli [22]. 
Determination of Phosphatidylcholine Biosynthesis Keratinocytes 
were treated with pulse-medium alone or with pulsc-mediu m containing 
HePC (10- 4_10- 6 Mol/ I) for 6 h. Pulse-medium contained [methyl-'HJ-
cholmc, 2.5 ,IlCi/ml. Cells were washed twice with ice-cold PBS (pH 7.2) 
and harvested, fo llowed by modified lipid extraction according to Bligh and 
Dyer [23]. After lyophil ization of tbe cells, 50,111 methanol, 25 tLl chloro-
form, and 20 J.L I water were added. Samples were stirred for 2 min on a 
vortex-mixer a nd centrifuged at 13,000 X g for 10 min. Phase separation 
was accomplished by addition of 25 J.L I chloroform and 25 ,111 water. The 
suspension and centri fugation steps werc repeated, and 15.ul of the chloro-
form phases were applied to si lica gel 60 high-performance thin-layer chro-
matography I?lates usmg a HPTLC applica tor (Linomat III; Camag, Berli n, 
Germany). LIpIds were separated according to Touchstone el al [24], using 
the solvent chloroform/methanoljacetic acid/ water (25:15:4:2, by vol-
ume). RadIOaCtiVIty was quantified by use of a thin-layer chromatography 
scan~er (Berthold LB 2821 HR, Wddbad, Germany). Phospholipids were 
Identified by caltbratmg the scanner with known standards. 
Measurement of the Distributi<:1D of CTP:Phospbocholine Cytidyl-
yltransferase The re leasc of cytldylyltransferase fro m keratinocytes was 
measured as described (25]. Cells were incubated for 6 h in 35-mm dishes 
with medium alone (contro l) or supplemented wi th 3 X 10- 6 Moljl HePC. 
Cells were then washed twice with 1 ml icc-cold PBS, and all the fo llowing 
steps were . carried out at 4 DC. Digitonin buffer (150 J.lI) containing 50 
mmoljl Tns-H CI (pH 7.4),150 mmoljl NaCI, 1 mmol/I ethylenediarnine-
tetraacetic acid (EDTA), 2 mmoljl dithiothreitol, 1 mmoljl phenylmethyl-
sulfonyl fluorid e (PMSF) , and 0.5 g/I digitonin was added. After incubation 
for 3 min, the digitonin supernatant was carefully removed. Undissolved 
digi tonin w~s pelleted at 2500 X .g for 5 min. The remaining ghosts of the 
cells m the dIshes were washed WIth 500 J.lI PBS, harvested in 35 J.LI buffer as 
described above (the harves ting buffer contai ned 0.03% Triton X-IOO and 
~o digitonin) , and were then homogenized using a dounce with a tight-fit-
tll1g plunger (~raun, Melslll:gen, Germany). Cytidylyltransferase activi ty 
was measured 111 the dlgltonm supernatants and in the cell ghost homoge-
nates by a mod~fied ~ethod of Sohal and Cornell [26] as described recently 
[25]. The reaction mIxture contamcd 50 m111ol/ 1 Tris-HCI, pH 7.4,0.03% 
Triton X- I00, 100 mmoljl NaCl, 10 mmoljl MgCI2' 3 mmol/I CTP, 1.5 
mmol/I [methyl.-14CJ-phosphocholinc (20 Bqjnmol), liposomes (400 
IllUoljll?hosphatldylcholme/400 J.lmolj l olcic ac id), a.nd 10 III of enzyme 
preparatIon m a final volumc of 55 J.l l. After incubating for 30 min at 37 D C, 
the reactlon was stol?ped by freez ing the samples in liquid nitrogen. The 
saml:'l es were Iyophdlzcd, dissolved in 20 J.LI methanol/ water (1 : I , v / v), and 
apphed t o HPTLC plates. After developing the plates in a solvent system 
contammg ~ethanoIj0.6% NaC1j25% aqueous NH, (8: 5: 1, by volume), 
the. radIOactIVIty was determined by radioscanning. One unit of enzyme 
activIty IS de~ned as nmol of COP-choline formed per min. From the data, 
the dlstnbutlOn of cytosolic and membrane-bound cytidylyltransferase ac-
tiVIty was calculated for each dish. 
RESULTS 
HePC Effects on Keratinocyte Proliferation and Protein 
Synthesis Treatment of second-passage keratinocytes with 
H ePC for 4 d under serum-free, low-Ca++ conditions induced a 
dose-dependent inhibition of cell pro liferation (Fig 2A). The mini-
ma.1 inhibitory HePC dose was 10- 7 M o ll l for thymidine incorpo-
ratIon and 3 X 10- 7 Moljl for the MUH assay. Complete inhibition 
of thymidine i ncorporation was o bserved after 10- 6 Moljl HePC, 
and after 10- 5 Moljl , no viable keratinocytes were detectable. In 
addition, H ePC dose-dependently inhibited cellular protein syn-
thesis, as shown by a significant decrease of methionine incorpora-
tion with a minimal inhibitory dose of 10- 6 Moljl (Fig 2B). 
In a second series of experiments, keratinocytes were grown 
under serum-free, hi gh-Ca++ conditions and treated identically 
with HePC to see whether the antiproliferative effects of HePC 
might be depe ndent upon the Ca++ concentration in th e culture 
m edium. We fo und that th e dose-dependent decrease of cellnum-
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Figure 2. Proliferation and protein synthesis of second-passage keratino-
cytes in serum-free, low-Ca++ medium after treatment with HePC for 4 d. 
A) Absolute fluorescence units (AFU) as determined by the MUH assay 
(opetl circle) and 3H-thymidine incorporation (CPM; open triangle). B) Incor-
poration of 35S-methionine. Bars, mean ± SD. 
bers was not influenced by increasing Ca++ concentrations (Fig 3), 
whereas there was a slight increase in the minimal effective dose 
necessa.ry to inhibit thymidine incorporation, as compared to low-
Ca++ conditions. 
The inhibitory effect of HePC on keratinocyte proliferation was 
time-dependent, as shown in Fig 4. Treatment with 10-5 Molll 
HePC inhibited thymidine incorporation after only 2 h, with a 
maximum effect after 72 h (Fig 4B), whereas a decrease of cell 
numbers, as measured by the MUH assay, was not observed until 
48 h later (Fig 4A). In contrast, inhibition of thymidine incorpora-
tion by 10-6 Molfl HePC was observed after 48 h (Fig 4B), with 
decreasing cell numbers after 72 h (Fig 4A). The earliestinhibitory 
effect on thymidine incorporation by treatment with 10-7 Molfl 
HePC was seen after 72 h, whereas cell numbers remained un-
changed for up to 96 h (Fig 4A,B). 
To prove the hypothesis that the growth inhibitory effect of 
HePC on keratinocytes might be dependent on the proliferative 
status of the celis, keratinocytes were grown under low-Ca++ con-
ditions until confluency and were then treated with HePC for 4 d. 
Indeed, confluent cultures that showed only minimal proliferation, 
as determined by thymidine incorporation and by the MUH assay, 
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were much less sensitive to HePC as compared to cultures treated 
during the logarithmic growth phase. HePC in concentrations up to 
10-4 Molll did not decrease cell numbers, and the thymidine incor-
poration was only reduced after 10-4 Molll HePC (data not shown). 
HePC Effects on Keratinocyte Phosphatidylcholine Biosyn· 
thesis To determine the effect of HePC on phosphatidylcholine 
biosynthesis of keratinocytes, we labeled the cells with [methyl-
3H)-choline and measured the incorporation of label into the or-
ganic phase of the cell extract. As demonstrated by HPTLC separa-
tion and radioscanning, approximately 95% of the label in the 
organic phase comigrated with the phosphatidylcholine standard 
and 5% with the sphingomyelin standard (data not shown). Treat-
ment of confluent second-passage keratinocyte cultures with HePC 
for 6 h dose-dependently inhibited the phosphatidylcholine biosyn-
thesis with a half inhibitory concentration of 3 X 10-6 Molll and a 
maximum inhibition observed after 3 X 10-5 Molfl (Fig 5). This 
inhibition of choline incorporation into phosphatidylcholine corre-
sponds to the data obtained on the subcellular distribution of the 
rate-limiting enzyme, CTP: phosphocholine cytidylyl transferase 
(Fig 6). HePC treatment resulted in a translocation of this enzyme 
to the cytosol, where the enzyme is inactive. 
DISCUSSION 
It was shown recently that the phospholipid analogue, hexadecyl-
phosphocholine (HePe), exerts an antineoplastic action in vitro and 
in vivo [3 - 7], especially in the to£ical treatment of skin metastases of 
human mammary carcinoma [8J. The present study demonstrates 
that HePC also inhibits the proliferation of non-transformed, nor-
mal human epidermal keratinocytes under serum-free culture con-
ditions. This was shown by a time- and dose-dependent reduction of 
the number of viable cells, as determined by the MUH fluorescence 
assay [20], as well as by inhibition of the incorporation of3H-thymi-
dine into DNA and by inhibition of protein synthesis, as determined 
by 35S-methionine incorporation. 
These data suggest that the antiproliferative effect of HePC i ll 
vitro is not selective for neoplastic cells. Moreover, the minimal 
concentrations necessary to reduce keratinocyte proliferation were 
markedly lower than those described for neoplastic ceil lines ill vitro 
[3,4,12J. This can be explained in part by the use of serum-free 
media in these experiments, as it had been reported that alkylphos-
pholipids are readily bound to serum albumin and serum lipopro-
teins, decreasing their uptake rate into the cells [1,14,15). Addi-
tional experiments showed that by using media supplemented with 
10% fetal calf serum, higher concentrations of HePC were needed 
for keratinocyte growth inhibition (data not shown). It did not 
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Figure 4. Proliferation of keratinocytes in low-Ca++ medium afte.r treat-
ment with HePC (10-5 -10-7 Mol/ l) for 2-96 h. A) AFU as detemuned by 
the MUH assay. B) 3H-thymidine incorporation. All values are expressed as 
percent of untreated controls. Bars, mean ± SO. 
appear that the growth inhibitory effect of HePC on keratinocytes 
was due to toxic effects because cells treated with HePC for up to 48 
h showed complete recovery within 12 h after the end of the trea~­
ment (data not shown). This indicates that HePC effects on keratl-
nocyte proliferation are reversible. 
It has been claimed that the i~1 vivo antiproliferative effects of 
HePC may be specific for neoplastic cells [5 - 7] . As neoplastic ceils 
are usually characterized by enhanced cell proliferation, as com-
pared to surrounding cellular elements, we hypothesized that the 
growth-inhibiting capacity of HePC might be correlated to. the 
proliferative status of the treated cells. Indeed, confluent keratmo-
eyte cultures that showed only minimal proliferative activity were 
much less sensitive to HePC than cultures treated during the loga-
rithmic growth phase. Therefore, the antiproliferative action of 
HePC seems to be rather selective for rapidly proliferating celis, and 
it is tempting to speculate that HePC might also be effective in 
non-neoplastic skin disorders characterized by epidermal hyperpla-
sia such as psoriasis. Preliminary clinical observations after topical 
application of HePC are compatible with this hYfothesis. 
The mechanisms of anti proliferative action 0 alkylphospholi-
pids have not yet been completely elucidated. We and others have 
shown that HePC inhibits protein kinase C irl vitro [11-13], an 
enzyme involved in the regulation of cell proliferation [27]. How-
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ever, our previous investigations suggested an additional mecha-
nism for the effects of HePC on Madin-Darby canine kidney ceils, 
demonstrating inhibition of phosphatidylcholine biosynthesis 
[16,25] . The present study demonstrated that HePC dose-depen-
dently inhibited the biosynthesis of phosphatidylcholine in kerati-
nocytes, suggesting plasma membranes as primary targets for the 
action of HePe. The decreased phosphatidylcholine biosynthesis 
was due to inactivation of the rate-limiting enzyme, CTP:phospho-
choline cytidylyltransferase, by translocation from membranes to 
the cytosol where the enzyme is inactive. Moreover, the antiprolif-
erative effect of HePC was not markedly modulated by increasing 
the Ca++ concentration of the culture media. 
These findings reveal alkylphospholipids as a new class of drugs 
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Figure 6. Distribution of CTP:phosphocholine cytidylyltransferase in ke-
ratinocytes grown ill serum-free, low-Ca++ medium after treatment with 
3 X 10-6 Molll HePC or medium control for 6 h. Cytidylyltransferase 
activity was measured in the digitonin supernatants and in the cell membrane 
homogenates as described in Materials alJd Methods. The distribution of cyti-
dylyltransferase was calculated in percent of total activity. Bars, mean ± SO. 
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inhibiting the proliferation of normal human epidermal keratino-
cytes. Unlike other cytostatic drugs, HePC-induced growth inhibi-
tion includes the inactivation of the membrane-bound enzyme 
CTP:phosphocholine cytidylyltransferase, thereby inhibiting 
phosphatidylcholine biosyn~hesis. Because the .antip:oli~erative ef-
fect of HePC il1 vitro was fairly specific for rapidly dlvldmg keratl-
nocytes, it is conceivable that HePC might also inhibit epidermal 
hyperplasia without markedly influencing surrounding normal tis-
sue after topical treatment ill vivo. Indeed, preliminary data confirm 
a beneficial effect of topical HePC application on skin metastases of 
mammary carcinomas without induction of epidermal atrophy in 
the surrounding areas [5,8]. As blood samples of patients treated 
with HePC were free of this compound, demonstrating lack of 
absorption even after extensive topical application [10], other skin 
disorders with neoplastic or non-neoplastic cellular hyperplasia 
might also be appropriate targets for topical therapy with HePC. 
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